Forte Biosciences (FBRX) Capital Expenditures (2016 - 2025)

Forte Biosciences (FBRX) has 7 years of Capital Expenditures data on file, last reported at $55000.0 in Q3 2025.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $55000.0 in Q3 2025; TTM through Mar 2026 was $55000.0, a 40.22% decrease from a year earlier, with the FY2025 full-year figure at $116000.0, up 213.51% from the prior year.
• Capital Expenditures for Q3 2025 stood at $55000.0, down from $61000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for FBRX reached as high as $61000.0 in Q1 2025 and fell as low as $6000.0 in Q1 2024.
• Historically, Capital Expenditures has averaged $35166.7 across 3 years, with a median of $36000.0 in 2023.
• Across the five-year window, Capital Expenditures surged 82.35% in 2024 and soared 916.67% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $17000.0 in 2023, then jumped by 82.35% to $31000.0 in 2024, then jumped by 77.42% to $55000.0 in 2025.
• Per Business Quant data, the three most recent Capital Expenditures figures were $55000.0 in Q3 2025, $61000.0 in Q1 2025, and $31000.0 in Q4 2024.